Concordia Healthcare Corp. T.CXR.R

Scotia set CXR target price US$75 and rated outperformance

[Qh1234]

Rating: Sector Outperform Target 1-Yr: US$75.00 ROR 1-Yr: 189.7%

due to IP, cannot post link.

[123Health]

Is this from 10/16/2015 ?????    If you cannot post the link (?) can you confirm the date the Scotia set this target.  Thanks.

[Qh1234]

the rating was evaluated on Feb 9, 2016

[fdfd12]

sorry but i have a few sites to check this and I can't find it on any of them.

[Qh1234]

I insert the link below. However, due to IP, I don't think you can access to that. https://www.solresearch.scotiabank.com/Fusion/PDFView?FeedId=5059&DocTag=CXRX.N~CXR.TO&VersionTag=2016210

[cg16]

wow, for Posters with so much to say about company information, "why is the stock falling then?... it must be something bad? ... the sellers must know something bad?" you would think that they would at least have direct access to reports on actual information (not made up in their minds) coming out? tells alot about a few posters... I confirm the Scotia report is legit. I received it at

[adamchess]

hi cg16, good post - All these questions seem very strange indeed. By all indications, AMCo is a first-class operation. Anyone can review their previous Annual Report online. They have won employment standards awards, etc. Given some time, I think Concordia and AMCo, as an important part of Concordia, will work together very well to improve overall revenues and profits and finances. No need to

[fdfd12]

I think that cashflow is more important than the EPS. Anyone agree with me? That 350M per year has to be reached to pay off the debt. This stock is down because of its debt and people betting that they wont be able to pay it off.

[adamchess]

Don't disagree with your comments fdfd - hopefully EPS and cashflow go hand in hand for the most part. It will be interesting to see their FS for the year. If CXR had no debt, it would be EPS over $11, and be worth at least $200 USD - a great disparity from current sp. Whether they succeed in paying off debt or become a takeover target, we should do extremely well holding under $60 CAD.

[fdfd12]

Remember, whoever takes them over will be resposible for that debt.

[cavinsin]

Yes I agree, cashflow is more important right now, and how it is used. Any good accountant can play with numbers/EBITDA, This is very vague, terminology, in my opinion,

[fdfd12]

This is frustrating. IBB up 2.5% and we are about to go under.

[cashflow98]

Good time to add some more IMO. Fdfd, Scotiabank re-iterated today a $75 USD target price. That is 3 times current SP. Day to day movements although frustrating do not matter to longs. Way to low to ignore much longer. Over $1B in revs with high single digit growth in USA and mid teens growth in rest of world. SP will increase in weeks to come. GLTA.

[Marcel7]

Agreed, quite frustrating. IBB goes down and sometimes we go down double or triple. IBB recovers or goes up and we go sideways? Doesn't make a lot of sense to me, as there doesn't seem to be a logical reason for this. I understand if market sentiment or the sector is driving us down, but by the same logic, it should also contribute to recovery as well.

[grox01]

It seems many here do read to much of the ups and downs of every days, hours, minutes of the stock price. Those that do... they will often trade to much. If you go the investment's way... just tune in every quarter to look at the facts, the real numbers and stay far from the noise that you keep reading here.

[cavinsin]

Grox, I disagree, if you have 100 shares I would not look at it until I retire, but if you lose new Ferrari in two days, of course you would like to know, minute by minute, what a heck is going on with the stock you own, glad I still sleep good, and so convince that I am on the right side of the trade. Just the matter of time, many Ferraris will be coming my way, daily.

[LuckyLuke1]

Americanbulls says Short CXRX and buy a Ferrari !

[123Health]

CalvinSin,  I totally get that.  But perhaps you missed an analyst on BNN this week who said that Concordia "took a Ferrari and turned it into a Hyundai" with the AMCo a acquition.  This is not the same company you originally invested in.  The story has changed and many are questioning the story in today's reality.   Whatever your position, I agree with Gros:

[sunshine7]

"analyst on BNN this week who said that Concordia "took a Ferrari and turned it into a Hyundai" with the AMCo a acquition." ... and Scotia bank who actually went though the numbers and business says otherwise. Who do you have faith in? AMCo is virtually untouched by the acquisition and only stands to benefit from an expanding product portfolio. Concordia benefits from reduced

[adamchess]

I think a better analogy is that Concordia has been transformed from a Ferrari into a Bentley after the acquisition. Everybody making noise like Concordia has a leaky muffler when it is just them making the noise. All healthcare stocks with smaller cap are vulnerable to hedge fund tactics trying to make easy money helped by Hillary. I doubt her comments were meant to target good corporate citizens

[grox01]

Cavinsin - When you think about it, you will come to the same conclusion... it doesn't have to matter if you own 100 shares or 1 000 000 shares. Do you think MT look at the minute by minute price action of the stock? You should feel confortable about your investment in CXR... as you have done your dd and you feel confindent about it's prospect. If you keep on writing about your

[puma1]

cannacord is the big sellor this week and make up 5% of the volume to date. they are a heavier resourc firm so you could see them moving out for shoring up other areas. as well a number of big people have left and perhaps they followed it? Goldman was a buyer last week and a sellor this week but for the month are still  up 360,000 shares net. all in all, the trades for the whole month are

[FootballFan1]

Since CXR didn't get roasted in front of a U.S Congressional Committee like VRX did, I guess you could say they have stayed out of the (unwelcome) spotlight, but isn't it the case that, like VRX, CXR counts on significant price increases on their drugs as a major driver of earnings and profit...?......How much of CXR's revenue comes from the USA..?....Is / was the USA the most

[sunshine7]

CXR stated that single digit growth in US market is expected. With the acquisition, they have dropped their US exposure from 100% to 40%. In EU they expect to see mid teen growth. These will be done with a combination of price increases, improved marketing of previously under marketed product and new products (60 in all). Since these are established drugs, there is less R&D burden and risk